Physician profile
Alejandro A Alvarez
NPI 1801873435
$4,413.78
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.74 · 2021: $924 · 2022: $2,018 · 2023: $522 · 2024: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.72 | 2021-2024 | Vraylar |
| Novo Nordisk INC | $416.16 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $402.59 | 2021-2024 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.89 | 2021-2023 | Stiolto Respimat, Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $252.19 | 2022-2024 | |
| Pfizer INC. | $222.76 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $213.07 | 2022 | |
| Glaxosmithkline, LLC. | $207.14 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Mylan Specialty L.P. | $183.53 | 2021-2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $152.03 | 2022-2024 | Xarelto |
| Boston Scientific Corporation | $145.03 | 2024 | Watchman Flx |
| Amgen INC. | $127.45 | 2021-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $120.62 | 2021-2024 | Breztri, Airsupra |
| Biohaven Pharmaceuticals, INC. | $107.60 | 2021 | |
| Merck Sharp & Dohme LLC | $98.84 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $88.59 | 2021-2022 | |
| Astellas Pharma US INC | $74.79 | 2021-2023 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $62.81 | 2021-2022 | |
| Shield Therapeutics INC | $52.84 | 2024 | |
| Dexcom, INC. | $48.91 | 2022-2024 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $37.15 | 2024 | Auvelity |
| Almatica Pharma LLC | $32.71 | 2022-2023 | Gralise, Sertraline Hcl, Loreev Xr |
| Idorsia Pharmaceuticals US INC | $29.51 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $21.64 | 2022 | |
| Exact Sciences Corporation | $21.29 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $17.54 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $15.00 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2022 | |
| Genentech USA, INC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.